Critical Pharmacodynamic Warning

dexfenfluramine affects the 2D6 metabolic pathway.

When patients take dexfenfluramine concurrently with drugs metabolized by 2D6, the risk of adverse effects may significantly increase. This interaction affects drug clearance and systemic exposure, potentially leading to toxicity or reduced therapeutic efficacy.

Clinical Impact: As a strong inhibitor , dexfenfluramine can alter the metabolism of substrate drugs, requiring careful monitoring and potential dose adjustments.

Clinical Overview for dexfenfluramine

This page outlines known interaction pathways involving dexfenfluramine, focusing primarily on its profile as a Strong inhibitor affecting the 2D6 pathway.

Enzyme Interaction Profile

dexfenfluramine demonstrates strong inhibitor potency against 2D6. Clinical significance of this interaction requires further evaluation.

Inhibitor

A substance that slows down or prevents an enzyme from metabolizing a drug. Inhibitors can lead to increased drug concentrations in the body, potentially causing toxicity or enhanced therapeutic effects.

Clinical Example: dexfenfluramine affects 2D6

Inducer

A substance that speeds up enzyme activity, causing drugs to be cleared from the body faster. Inducers can reduce drug effectiveness by lowering concentrations below therapeutic levels.

Interaction Details
Drug Name dexfenfluramine
Affected Enzyme 2D6
Inhibitor Strength Strong inhibitor Unknown
Inducers No inducers listed
Inhibitors fluoxetine
Clinical Recommendations

Consult primary literature for guidance.

Monitoring Parameters:
  • Therapeutic drug levels
  • Adverse effect monitoring
  • Clinical response assessment
Dose Considerations:
  • Consider dose reduction
  • Evaluate alternative therapies
  • Adjust based on response
Quick Facts
Interaction ID
4884
Primary Pathway
2D6
Interaction Type
Enzyme Inhibition
Clinical Phase
Unknown
Clinical Significance

Clinical significance requires further evaluation.

Information Sources
  • FDA Drug Interaction Database
  • Clinical Pharmacology Guidelines
  • Pharmaceutical Labeling Information
  • Published Clinical Studies

Last updated: June 12, 2026